Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study

Jason Bacharach; Shane R Kannarr; Anthony Verachtert; Preeya K Gupta; Moataz Razeen; Megan E Cavet; Jason L Vittitow; Jacob Lang; Thomas M Chester; Jillian F Ziemanski; Darrell E White

doi:10.1007/s40123-025-01097-z

Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study

Ophthalmol Ther. 2025 Apr;14(4):693-704. doi: 10.1007/s40123-025-01097-z. Epub 2025 Feb 22.

Authors

Affiliations

¹ North Bay Eye Associates, Inc., 104 Lynch Creek Way, Suite 15, Petaluma, CA, 94954, USA. jbacharach@northbayeye.com.
² Kannarr Eye Care, Pittsburg, KS, USA.
³ Moyes Eye Center, Kansas City, MO, USA.
⁴ Triangle Eye Consultants, Raleigh, NC, USA.
⁵ Bausch + Lomb, Bridgewater, NJ, USA.
⁶ Associated Eye Care, Hudson, WI, USA.
⁷ Cleveland Eye Clinic, Brecksville, OH, USA.
⁸ Department of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, AL, USA.
⁹ Skyvision Centers, Westlake, OH, USA.

Abstract

Introduction: Perfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms of dry eye disease (DED) and targets excessive tear evaporation. This study evaluated patient-reported outcomes early in treatment with PFHO.

Methods: This prospective, multicenter, open-label, phase 4 study enrolled adults with a history of DED for ≥ 6 months. PFHO was instilled in both eyes four times daily for 14 days. Patients completed early outcome surveys during four clinic visits (day 1 [pretreatment; 5 and 60 min post-PFHO instillation] and days 3, 7, and 14). Symptom severity, symptom frequency, and treatment satisfaction were rated on visual analog scales (range 0-100). The primary endpoint was mean change from baseline in overall DED symptom severity at day 7. Secondary endpoints included change in severity of individual DED symptoms (eye dryness, blurred vision, eye irritation, light sensitivity, eye tiredness, burning/stinging, eye itching, eye pain); change in frequency (measured as percentage of time experienced) of the most bothersome symptom, awareness of dry eye symptoms, and fluctuation in quality of vision; and treatment satisfaction.

Results: Ninety-nine patients enrolled (85.9% female; age range 35-81 years). The primary endpoint was met: mean (SD) overall symptom severity decreased significantly from 72.1 (17.0) at baseline to 27.8 (22.3) at day 7 (mean change, - 44.5; P < 0.0001). Mean (SD) percentage of time experiencing the most bothersome symptom decreased from 77.9% at baseline to 34.7% at day 14 (P < 0.0001). Significant reductions in severity and frequency also were observed for all symptoms at all postbaseline assessments (P < 0.0001). Median ratings of treatment satisfaction were 83.0 at day 3, 86.0 at day 7, and 90.0 at day 14.

Conclusion: Early in the course of treatment with PFHO, patients with DED experienced significant reductions in dry eye symptom frequency and severity. Treatment satisfaction with PFHO was high.

Trial registration: ClinicalTrials.gov identifier NCT06309953.

Keywords: Dry eye; Patient-reported outcomes; Perfluorohexyloctane; Symptoms.

Associated data

ClinicalTrials.gov/NCT06309953

Abstract

Associated data

Grants and funding